Munich, Bavaria, Germany · Hybrid
Controller (m/f/d) Nuclidium AG is pioneering copper-based theranostics with its platform, developing a fully integrated diagnostic and therapeutic approach using Copper-61 (PET imaging) and Copper-67 (therapy). We are a…
Skills: Financial Closing, IFRS, HGB, Financial Reporting, Audit Coordination
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Controller is responsible for owning the monthly, quarterly, and annual closing processes and preparing comprehensive financial statements. They will also manage financial reporting for management and investors, ensure tax and audit compliance, and optimize finance systems and processes.
Candidates need 8-10 years of experience in accounting or controlling with strong technical knowledge of accounting standards and audit processes. A degree in Finance, Accounting, or Business Administration is required, along with fluency in both German and English.
Nuclidium AG is pioneering copper-based theranostics with its platform, developing a fully integrated diagnostic and therapeutic approach using Copper-61 (PET imaging) and Copper-67 (therapy). We are advancing a differentiated clinical pipeline targeting solid tumors with high unmet need while building a sustainable, global radionuclide production and manufacturing network. Following a Series B financing, Nuclidium is scaling its operations across Europe, North America and beyond.
We are seeking a Controller to work closely with the CFO and senior management, ensuring flawless financial operations across all legal entities and assets.
\nKey ResponsibilitiesSetting a new standard in precision oncology
Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Offices: Bäumleingasse, Basel, BS 4051, CH · Munich, Munich, DE
Setting a new standard in precision oncology
Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Offices: Bäumleingasse, Basel, BS 4051, CH · Munich, Munich, DE